Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

Jun Zhou1,2,3, Kathleen M. Mahoney1,4, Anita Giobbie-Hurder3,5, Fengmin Zhao5, Sandra Lee5, Xiaoyun Liao3,6, Scott Rodig3,6, Jingjing Li1,2,3, Xinqi Wu1,2, Lisa H. Butterfield7,8, Matthias Piesche1,9, Michael P. Manos2,3, Lauren M. Eastman2,3, Glenn Dranoff10, Gordon J. Freeman1,3, and F. Stephen Hodi1,2,3

Abstract

Blockade of the pathway including programmed death-ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) has produced clinical benefits in patients with a variety of cancers. Elevated levels of soluble PD-L1 (sPD-L1) have been associated with worse prognosis in renal cell carcinoma and multiple myeloma. However, the regulatory roles and function of sPD-L1 particularly in connection with immune checkpoint blockade treatment are not fully understood. We identified four splice variants of PD-L1 in melanoma cells, and all of them are secreted. Secretion of sPD-L1 resulted from alternate splicing activities, cytokine induction, cell stress, cell injury, and cell death in melanoma cells. Pretreatment levels of sPD-L1 were elevated in stage IV melanoma patient sera compared with healthy donors. High pretreatment levels of sPD-L1 were associated with increased likelihood of progressive disease in patients treated by CTLA-4 or PD-1 blockade. Although changes in circulating sPD-L1 early after treatment could not distinguish responders from those with progressive disease, after five months of treatment by CTLA-4 or PD-1 blockade patients who had increased circulating sPD-L1 had greater likelihood of developing a partial response. Induction of sPD-L1 was associated with increased circulating cytokines after CTLA-4 blockade but not following PD-1 blockade. Circulating sPD-L1 is a prognostic biomarker that may predict outcomes for subgroups of patients receiving checkpoint inhibitors. Cancer Immunol Res; 5(6); 480–92. © 2017 AACR.

Introduction

Programmed death-ligand 1 (PD-L1) is a membrane-bound protein primarily expressed on dendritic cells (DC) and monocytes (1). Its receptor, programmed cell death protein 1 (PD-1), is expressed on activated T cells and B cells, DC, and monocytes (1). As T cells engage with the antigen/MHC complex, binding of PD-1 to PD-L1 inhibits T-cell activation, leading to immune suppression (1, 2). A wide range of tumors express PD-L1 (3–6). Although conflicting reports exist for melanoma (7), PD-L1 expression is associated with worse clinical outcomes in some tumor types (8, 9). Blocking the PD-1/PD-L1 interaction increases antigen-specific T-cell activity whereas decreasing Treg suppressive function (10, 11). Antibodies that block either PD-1 or PD-L1 improve clinical responses as well as patients’ overall survival in many tumor types (12–16).

Soluble PD-L1 (sPD-L1) in sera is associated with aggressive renal cell carcinoma and shorter survival in multiple myeloma and diffuse large B-cell lymphoma (17–19). sPD-L1 can be produced by cytokine-activated mature DCs in vitro (20). However, the mechanisms by which sPD-L1 in patients are generated remain poorly understood. The clinical significance of circulating sPD-L1 in melanoma is unknown. A splice variant of PD-L1, which lacks the IgV domain by splicing out exon 2 (21), is likely neither secreted nor functional, because it retains the transmembrane domain but lacks the PD-1 binding site within the IgV domain. An additional variant with splicing regions in exons 3 and 4 is documented in Genbank (Accession: AY714881). Here, we identify four splice variants of PD-L1 in melanoma and investigated production of sPD-L1 in patients receiving immune checkpoint blockade.

Materials and Methods

Cell lines

A375, K008, K028, K029, K033, M34, and UACC257 melanoma cell lines were cultured in DMEM medium with 10% fetal bovine serum. 293T cells were cultured in complete DMEM. Human melanoma cells were isolated from tumor biopsies of melanoma patients, and the human melanoma cell lines were

Note: Supplementary data for this article are available at Cancer Immunology Research Online (http://cancerimmunoresearch.aacrjournals.org/).

Corresponding Author: F. Stephen Hodi, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Phone: 617-632-5053; Fax: 617-582-7992; E-mail: stephen_hodi@dfci.harvard.edu
doi: 10.1158/2326-6066.CIR-16-0329
©2017 American Association for Cancer Research.
developed approximately 25 years ago in accordance with Dana-Farber/Harvard Cancer Center Institutional Review Board approved protocols. UACC257 cells were kindly provided by Dr. David E. Fisher from Massachusetts General Hospital, Boston, 11 years ago. A375 cells were obtained from ATCC 10 years ago. The identities of the PCR products were confirmed by sequencing (Eton Bioscience Inc.).

**Transfection, lentiviral production, and lentiviral transduction**

The pELNS expressing PD-L1 variants were cotransfected into 293T cells with three packaging plasmids expressing gag/pol, VSV-G, and REV using TransfectIT 293 (Mirus). Lentiviral supernatants were collected and filtered. PD-L1-1, PD-L1-3, and PD-L1-9 were transduced into 1 × 10^5 A375 cells with the supernatant in the presence of 8 μg/mL Polybrene (EMD Millipore).

**Immunoprecipitation, SDS-PAGE, and immunoblotting**

For BRAF resistant cell line studies, approximately 8 × 10^7 PLX4032 resistant A375 and 1 × 10^7 PLX4032 resistant M34 melanoma cell lines were cultured in complete DMEM medium in the presence of 1 μg/mL PLX4032 for 2 days. After washing with PBS three times, the cells were further cultured in Opti-MEM reduced serum medium (Life Technologies) in the presence of 1 μg/mL PLX4032 for 2 days. For cytokine induction studies, approximately 5–30 × 10^6 cells (A375, K008, K028, and UACC257) were cultured in complete DMEM medium for 2 days. After washing with PBS three times, the melanoma cell lines were cultured in Opti-MEM reduced serum medium in the presence of either 200 μJ/mL IFNγ (Biolegend), or 2000 μJ/mL IFNα (EMD Millipore), or 10 ng/mL TNFα (R&D systems) for an additional 2 days. The culture media were collected, and concentrated with a 3K cutoff Centriprep spin column (EMD Millipore). Samples were normalized by cell numbers. Concentrated supernatant was incubated with 0.5 μg anti-human PD-L1 mAb (clone 29E.2A3, Biolegend) and 10 μL protein G plus agarose (Santa Cruz Biotechnology) at 4 °C overnight. After washing with PBS, the agarose beads were resuspended in Laemmli’s reducing buffer (Boston Bioproducts), and further heated. Immunoprecipitated proteins were subjected to 12% SDS-polyacrylamide gel electrophoresis (PAGE), and transferred onto PVDF membranes. The membranes were immunoblotted overnight at 4 °C with a biotinylated goat anti-human PD-L1 at 0.1 μg/mL (R&D systems), and further incubated with HRP-conjugated streptavidin at 2.5 μg/mL (Jackson ImmunoResearch) at room temperature for 2 hours. The protein bands were detected by chemiluminescence (PerkinElmer).

**PD-L1/Fc fusion protein**

C02 and C03 domains of human IgG1 were fused to PD-L1-1, PD-L1-3, PD-L1-9, and PD-L1-1/Fc in the presence of 8 μg/mL Polybrene (EMD Millipore), respectively. PD-L1-3/Fc, PD-L1-9/Fc, and PD-L1-1/Fc were purified with protein A agarose (Life Technologies). It was further confirmed by SDS-PAGE and Coomassie staining, and by immunoblotting with anti-human PD-L1 mAb (29E.1DS) (Supplementary Fig. S2A and S2B).

**Proliferation assay**

To generate activated T cells, human naive CD4^- or CD8^- T cells were treated with 10 μg/mL PHA for 3 days and further rested overnight. A total of 1 × 10^6 cells/well of PHA-activated CD4^- or CD8^- T cells were stimulated with 5 μg/mL coated anti-CD3 (BD Biosciences) in the absence or presence of 10 μg/mL coated either recombinant fusion proteins of PD-L1 variants or human IgG for 3 days, and further pulsed with [3H]thymidine (0.25 μCi/μL) for 6 hours. The incorporated radioactivity was measured in a liquid scintillation counter (Wallac 1450 Microbeta Trilux, Perkin Elmer).
incubated overnight at 4°C. Plates were then washed with PBS and blocked with protein-free blocking buffer (Pierce) for 4 hours. Patient sera or plasma were diluted with PBS in 1:1 volume ratio. One-hundred microliters per well of diluted patient sera or plasma was added and incubated overnight at 4°C. Plates were washed with PBS containing Tween-20, and incubated with 100 μL per well of 0.1 μg/well biotinylated anti–PD-L1 mAb (29E2A3, Biolegend) in protein-free blocking buffer at room temperature for 2 hours. Plates were then washed and incubated with 1 mg/mL streptavidin-HRP (Jackson ImmunoResearch) diluted 1:4,000 in protein-free blocking buffer for 2 hours. Plates were washed and treated with biotinyl tyramide (Perkin Elmer) for 30 minutes, and then washed and incubated with 1 mg/mL streptavidin-HRP (Jackson ImmunoResearch) diluted 1:400,000 in protein-free blocking buffer for 2 hours with further development with TMB (Pierce). Plates were read at an optical density (O.D.) of 450 nm. All samples were assayed in duplicate. A standard curve using recombinant human PD-L1-HIS (Novoprotein) was also performed with each assay.

Cytokine Luminox assay
IFNα, IFNγ, and TNFα in plasma of melanoma patients were quantified by a Luminox beads kit (EMD Millipore). Twenty-five microliters/well of antibody coupled beads and 50 μL/well of diluted patient plasma were added into a 96-well plate and incubated overnight at 4°C. Plates were processed following manufacturer’s instruction and read by Luminox 200 (Luminox Corporation). All samples were performed in duplicate. The standard curves were also performed with each assay.

Statistical analyses
ELISAs were conducted in duplicate to examine sPD-L1 in patient serum samples. A value of 0.1 ng/mL was determined to be the lower limit of detection on the basis of sensitivity of the ELISA assay. If assay values were <0.1 ng/mL, 0.01 ng/mL was substituted. Clinical comparisons addressed two hypotheses: (i) high levels of sPD-L1 were associated with progressive disease; and (ii) long-term or delayed increases in sPD-L1 were associated with favorable clinical response. Data from the ipilimumab plus bevacizumab trial were used as a test set; data from E1608 and E1609 were used as a validation set. Division points for pretreatment sPD-L1 were based on the test set and were selected to determine the distribution of high levels of sPD-L1 in both A375 and M34 melanoma cell lines (Fig. 1). The PD-L1-3 variant has been previously reported in Genebank (Accession: AY714881). The PD-L1-1 variant has a 66-bp deletion from nucleotide (nt)-791 to 850 of PD-L1 (Fig. 1). This deletion removes 20 amino acids of the intracellular domain. The splice occurs from the end of exon 4 to the middle of exon 6, deleting exon 5 and half of exon 6. The PD-L1-12 variant has a splice in the extracellular domain resulting in a 106-bp deletion from nt-531 to 636 within the exon 3 region, resulting in a frame shift leading to a stop codon 4 nt after nt-530 in exon 3. The resulting protein is truncated before the transmembrane domain and terminates with a different amino acid. PD-L1-9 has lost a 66-bp region from nt-725 to 790 in exon 4. This results in a frame shift leading to a stop codon 4 nt after nt-724 before the transmembrane domain, and adding two additional amino acids at the end. Variant PD-L1-3 has both the splices of PD-L1-9 and PD-L1-12, but encodes the same protein as PD-L1-12, as the second splice occurs after the stop codon of PD-L1-3.

We used primers specific to the splice variants to examine their expression in six melanoma cell lines. Five of the melanoma cell lines expressed all of the variants. The sixth line, K029, lacked variant PD-L1-9 (Supplementary Fig. S2C). Thus, PD-L1 splice variants are generally expressed in melanoma.

Secretion of PD-L1 variants
Because splice variants lacking the transmembrane domain could be secreted, we assayed culture supernatants of cell lines A375, K008, K028, M34, and UACC257 for sPD-L1. Three PD-L1 bands of 24, 38, and 45 kDa were detected in the culture medium of all cell lines. PD-L1-3 and PD-L1-9 corresponded to the 24 and 38 kDa bands, respectively. A375 cells, in which PD-L1-3 and PD-L1-9 were overexpressed, secreted more sPD-L1 than did parental or mock-infected cells (Fig. 2A and B). Thus, these melanoma cell lines secrete sPD-L1 variants.

Overexpression of PD-L1-1 in A375 cells not only increased the membrane-bound form (Supplementary Fig. S2D), but also increased the soluble 38 and 45 kDa bands in the culture medium (Fig. 2B). Secretion of sPD-L1 may result from alternative spliced variants of the PD-L1 transcript.

Biologic activity of sPD-L1
PD-L1 inhibits T-cell activation. To assess the function of the sPD-L1 variants, we stimulated PHA-activated human CD4+ and CD8+ T cells with anti-CD3 in the absence or presence of either fusion proteins of PD-L1 variants (Supplementary Fig. S2A and S2B) or human IgG1 for 3 days. Activated CD4+ and CD8+ T cells between healthy donors and melanoma patients. The comparisons of clinical response according to categories of pretreatment levels or on-treatment increases in sPD-L1 were carried out with Fisher exact tests. Comparisons of sPD-L1 levels according to response were based on Kruskal–Wallis tests. The distribution of overall survival was summarized using the method of Kaplan–Meier; comparisons of survival according to pretreatment or on-treatment sPD-L1 classes were based on log-rank tests. All tests were two-sided, and P < 0.05 was considered statistically significant.

Results
Splice variants of PD-L1 in melanoma
We identified four splice variants in addition to full-length PD-L1 in both A375 and M34 melanoma cell lines (Fig. 1). The PD-L1-3 variant has been previously reported in Genebank (Accession: AY714881). The PD-L1-1 variant has a 66-bp deletion from nucleotide (nt)-791 to 850 of PD-L1 (Fig. 1). This deletion removes 20 amino acids of the intracellular domain. The splice occurs from the end of exon 4 to the middle of exon 6, deleting exon 5 and half of exon 6. The PD-L1-12 variant has a splice in the extracellular domain resulting in a 106-bp deletion from nt-531 to 636 within the exon 3 region, resulting in a frame shift leading to a stop codon 4 nt after nt-530 in exon 3. The resulting protein is truncated before the transmembrane domain and terminates with a different amino acid. PD-L1-9 has lost a 66-bp region from nt-725 to 790 in exon 4. This results in a frame shift leading to a stop codon 4 nt after nt-724 before the transmembrane domain, and adding two additional amino acids at the end. Variant PD-L1-3 has both the splices of PD-L1-9 and PD-L1-12, but encodes the same protein as PD-L1-12, as the second splice occurs after the stop codon of PD-L1-3.

We used primers specific to the splice variants to examine their expression in six melanoma cell lines. Five of the melanoma cell lines expressed all of the variants. The sixth line, K029, lacked variant PD-L1-9 (Supplementary Fig. S2C). Thus, PD-L1 splice variants are generally expressed in melanoma.

Secretion of PD-L1 variants
Because splice variants lacking the transmembrane domain could be secreted, we assayed culture supernatants of cell lines A375, K008, K028, M34, and UACC257 for sPD-L1. Three PD-L1 bands of 24, 38, and 45 kDa were detected in the culture medium of all cell lines. PD-L1-3 and PD-L1-9 corresponded to the 24 and 38 kDa bands, respectively. A375 cells, in which PD-L1-3 and PD-L1-9 were overexpressed, secreted more sPD-L1 than did parental or mock-infected cells (Fig. 2A and B). Thus, these melanoma cell lines secrete sPD-L1 variants.

Overexpression of PD-L1-1 in A375 cells not only increased the membrane-bound form (Supplementary Fig. S2D), but also increased the soluble 38 and 45 kDa bands in the culture medium (Fig. 2B). Secretion of sPD-L1 may result from alternative spliced variants of the PD-L1 transcript.

Biologic activity of sPD-L1
PD-L1 inhibits T-cell activation. To assess the function of the sPD-L1 variants, we stimulated PHA-activated human CD4+ and CD8+ T cells with anti-CD3 in the absence or presence of either fusion proteins of PD-L1 variants (Supplementary Fig. S2A and S2B) or human IgG1 for 3 days. Activated CD4+ and CD8+ T cells...
Figure 1.

A. Schematic diagram of identified splice variants of PD-L1. The full-length of PD-L1 consists of six exons. The transmembrane domain (TM) is located in exon 4 and marked in pink. Spliced-out regions of PD-L1-1, 3, 9, and 12 are indicated with bracket symbols. Stop represents a stop codon.

B. Identification of splice variants of human PD-L1. PD-L1 transcripts from A375 and M34 melanoma cell lines were generated by RT-PCR and cloned into a TA TOPO vector. Four unique PD-L1 splice variants were identified by sequencing. Three splice variants PD-L1-1, PD-L1-9, and PD-L1-12 have not been previously reported. The full-length nucleotide and amino acid sequence for membrane-bound PD-L1 are represented (top). The transmembrane domain is shown in pink. Spliced-out regions are indicated with bracket symbols and shown in red. In each of the identified splice variants, the amino acid sequences are shown in blue. Underlines indicate additional different amino acids.

Soluble PD-L1 in Melanoma

www.aacrjournals.org Cancer Immunol Res; 5(6) June 2017 483

Published OnlineFirst May 18, 2017; DOI: 10.1158/2326-6066.CIR-16-0329

Downloaded from cancerimmunolres.aacrjournals.org on December 21, 2021. © 2017 American Association for Cancer Research.
showed less activation when treated with PD-L1 variants than with human IgG1 (Fig. 2C). Membrane-bound full-length PD-L1 abrogated ML-IAP antigen-specific CD8^+ T cell (25) activation and proliferation in A375 and K028 cells (Supplementary Fig. S3A–C). Although not as potent as full-length membrane-bound PD-L1, sPD-L1 variants exhibit inhibitory functions on T-cell activation and proliferation.

Alternative spliced variants of V600E BRAF have been reported in BRAF inhibitor resistant melanoma tumors (26). To examine whether BRAF inhibitor–resistant melanoma cell lines induced sPD-L1 expression, culture medium from PLX4032-resistant A375 and M34 cells were analyzed. The M34 parental cells produced modest amounts of the 38 and 45 kDa sPD-L1, which was increased about 4.6-fold in the PLX4032 resistant M34 cells (Fig. 2D). Although concentrations of the 38 and 45 kDa sPD-L1 variants were relatively high in parent supernatants, expression of the 24 kDa sPD-L1 variant increased about 2-fold in supernatants from PLX4032-resistant A375 cells (Fig. 2D).
To assess the effects of cytokines, such as IFNγ (which induces PD-L1) on the secretion of sPD-L1 variants, cell lines A375, K008, K028, and UACC257 were cultured in the absence or presence of IFNγ (200 U/mL), IFNζx (2,000 U/mL), or TNFx (10 ng/mL) for 2 days. The 38 and 45 kDa bands of sPD-L1 were increased 4 or 2.3-fold by IFNγ treatment, 2.7 or 1.3-fold by IFNζx, and 1.6 or 1.2-fold by TNFx, in supernatants from cell lines A375 and K008, respectively (Fig. 2E and F). The 38- and 45-kDa bands of PD-L1 in supernatant from K028 were increased by about 14-fold with IFNγ or TNFx treatments and by 6.6-fold with IFNζx treatment (Fig. 2G). The 38- and 45-kDa bands increased in cell line UACC257 supernatants 6.3- or 4.7-fold with IFNγ or IFNζx treatments, respectively, and the 24-kDa band increased 2.2-fold with IFNζx treatment (Fig. 2H). Different melanoma cell lines appeared to produce different sPD-L1 variants in response to different cytokine treatment.

Cytokine treatment of A375, K028, and UACC257 melanoma cell lines resulted in increased secretion of sPD-L1, as well as increased expression of cell surface PD-L1 and decreased cell proliferation (Fig. 2E, G, and H; Supplementary Fig. S4A–S4C). K008 cells constitutively express PD-L1, but express sPD-L1 in response to cytokine treatment (Fig. 2F; Supplementary Fig. S4D). Thus, cytokines induced expression of both sPD-L1 and PD-L1 in a dose-dependent manner in melanoma cell lines (Supplementary Fig. S5A–S5F).

The expression of cell surface PD-L1 parallels expression of sPD-L1 in melanoma cell lines without cytokine treatment (Supplementary Figs. S4 and S5G), and is inducible by sodium azide (Supplementary Fig. S6). We suggest that secretion or release of sPD-L1 can result from BRAF-resistance mechanisms, cytokine induction, cell stress or cell injury, or cell death.

Development of sPD-L1 ELISA

We developed ELISA assays with two capture antibodies that detect PD-L1 variants. Specificity was assayed with concentrations of recombinant PD-L1 (Novoprotein), PDL2 (Novoprotein), ML-IAP (R&D systems), and human IgG1 (SouthernBiotech) ranging from 0.001 ng/mL to 100 ng/mL (Supplementary Fig. S7A and S7B). Mouse anti-PD-L1 mAbs, clone 29E.12B1, and 130021 were used as a positive control.

Immunoprecipitation, SDS-PAGE, and immunoblotting analyses on sPD-L1 in plasma from melanoma patients. sPD-L1 from the culture medium of A375 melanoma cell line was used as a positive control.

To confirm the presence of sPD-L1 variants in melanoma patient plasma, immunoblot analysis of the immunoprecipitant from patient P173 detected a high concentration (1.87 ng/mL) of sPD-L1all but no (<0.1 ng/mL) sPD-L1L in pretreatment plasma. This is consistent with the banding pattern of sPD-L1-3 or sPD-L1-12 (Fig. 3B, left). In pretreatment plasma from patient P21, both isoforms of sPD-L1all (14.63 ng/mL) and sPD-L1L (0.94 ng/mL) were detected, which is consistent with the banding pattern when sPD-L1-3, sPD-L1-12, and sPD-L1-9 were assayed by immunoblot (Fig. 3B, right).

sPD-L1 levels in melanoma patients

sPD-L1 in samples from 25 healthy donors and 65 untreated stage IV melanoma patients were analyzed. Concentrations of sPD-L1**all** were elevated in the plasma of melanoma patients in comparison with healthy donors (P = 0.04, Fig. 3A). Circulating sPD-L1L was undetectable (<0.1 ng/mL) in most, but not all, melanoma patients, similar to healthy donors.

To confirm the presence of sPD-L1 variants in melanoma patient plasma, immunoblot analysis of the immunoprecipitant from plasma was performed. For example, ELISA assay on patient P173 detected a high concentration (1.87 ng/mL) of sPD-L1**all** but no (<0.1 ng/mL) sPD-L1L in pretreatment plasma. This is consistent with the banding pattern of sPD-L1-3 or sPD-L1-12 (Fig. 3B, left). In pretreatment plasma from patient P21, both isoforms of sPD-L1**all** (14.63 ng/mL) and sPD-L1L (0.94 ng/mL) were detected, which is consistent with the banding pattern when sPD-L1-3, sPD-L1-12, and sPD-L1-9 were assayed by immunoblot (Fig. 3B, right).

sPD-L1 levels in melanoma patients on immune checkpoint blockade

To explore the clinical significance of sPD-L1 in patients with melanoma on ipilimumab-based therapy, we first analyzed plasma specimens collected from 42 patients on the ipilimumab (3 mg/kg or 10 mg/kg) combined with bevacizumab (7.5 mg/kg or 15 mg/kg) clinical trial (NCT00790010; ref. 22). Pretreatment levels of sPD-L1 were determined before starting checkpoint immunotherapy. On the basis of sensitivities and the lower limit of detection of the ELISA assays, pretreatment levels of sPD-L1,
and clinical outcomes, the patients were divided into three groups: undetectable/low, moderate, and high sPD-L1. For sPD-L1 all, groups were divided into <0.5 ng/mL (low), ≥0.5 ng/mL and <1.4 ng/mL (moderate), and ≥1.4 ng/mL (high). For sPD-L1 L, groups were divided into <0.1 ng/mL (low), ≥0.1 ng/mL and <0.5 ng/mL (moderate), and ≥0.5 ng/mL (high). All patients with high pretreatment levels of either sPD-L1 all or sPD-L1 L experienced progressive disease (PD; Fisher exact test $P = 0.0015$ and 0.025, respectively; Table 1A and 1B; Supplementary Fig. S10).

We next sought to investigate kinetic changes of sPD-L1 in patients as a function of treatment. We began with a cohort of patients treated with ipilimumab plus bevacizumab (NCT00790010; ref. 22). Among the five patients with high pretreatment concentrations of sPD-L1 all and the three patients with high pretreatment sPD-L1 L, patients after treatment showed either unchanged, or increased, or decreased sPD-L1 all and sPD-L1 L (Fig. 4A; Supplementary Fig. S10A and S10B). To investigate the associations between sPD-L1 all and immunologic responses, we examined the kinetic changes of cytokines in plasma samples in relation to changes in sPD-L1. Patients with high pretreatment concentrations of sPD-L1 all showed either decreased or no change in circulating cytokine production after treatment (Fig. 4A; Supplementary Figs. S10A–S10H and S11), suggesting that high pretreatment concentrations of sPD-L1 all may suppress effective antitumor immunity directly or may be a proxy for a state of dominant immune inhibition.

Whether the increases in sPD-L1 may be a pharmacodynamic marker and related to clinical outcomes regardless of the pretreatment concentration of sPD-L1 was next explored. Fourteen patients experienced ≥1.5-fold increases in either sPD-L1 all or sPD-L1 L following treatment with ipilimumab–bevacizumab (Figs. 4B and 5; Supplementary Fig. S10A–S10F). Four of five patients who had ≥1.5-fold increases in either sPD-L1 all or sPD-L1 L within 4.5 months showed progressive disease (Supplementary Fig. S10A–S10F). Eight patients who had increases in either sPD-L1 all or PD-L1 L after 5 months of treatment experienced favorable clinical responses and corresponding increases in cytokines, and patients with <1.5-fold increases in sPD-L1 all experienced less favorable outcomes (Figs. 4B and 5; Supplementary Figs. S10A–S10F and S11). Landmark analyses indicated significant associations between the increases of sPD-L1 all and partial responses (Fisher exact test $P = 0.02$ and 0.006 for sPD-L1 all and sPD-L1 L analyses, respectively, Fig. 5A and B; Supplementary Fig. S10G and S10H). The peak posttreatment sPD-L1 all corresponded with clinical disease regressions (Fig. 4B, bottom). In patients without increasing sPD-L1, increases in cytokines after 5 months of treatment were associated with stable disease (Supplementary Figs. S10 and S11). We suggest that functional immune activation, as assessed by induction of sPD-L1, can be associated with cytokine production from the immune activation that resulted from treatment.

To further investigate the role of sPD-L1 related to ipilimumab alone, 23 patients who received ipilimumab (dose 3 mg/kg) were studied. Two patients with high pretreatment concentrations of sPD-L1 all experienced progressive disease. The single patient with high pretreatment sPD-L1 L experienced stable disease, but only had 12 months survival (Supplementary Fig. S12A–D). Only two patients had partial responses: patients P187 and P169 (Supplementary Fig. S12C–D). Patient P187 had a ≥1.5-fold increase of sPD-L1 all at 4 months. Although this patient survived 29 months, no further samples were available. Patient P169’s sPD-L1 all both

### Table 1. Associations between pretreatment levels of sPD-L1 and clinical responses.

<table>
<thead>
<tr>
<th>Association between pretreatment levels of sPD-L1 all and clinical responses</th>
<th>sPD-L1 all of pretreatment (baseline, ng/mL)</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1.4</td>
<td>8 (23%)</td>
<td>21 (57%)</td>
<td>8 (22%)</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>≥1.4</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>5 (100%)</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Fisher exact test $P = 0.0015$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C. Ipilimumab or ipilimumab plus sargramostim</th>
<th>sPD-L1 all of pretreatment (baseline, ng/mL)</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1.4</td>
<td>32 (23%)</td>
<td>32 (23%)</td>
<td>77 (54%)</td>
<td>141</td>
<td></td>
</tr>
<tr>
<td>≥1.4</td>
<td>0 (0%)</td>
<td>1 (0%)</td>
<td>9 (90%)</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Fisher exact test $P = 0.04$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E. Anti-PD-1 antibody</th>
<th>sPD-L1 all of pretreatment (baseline, ng/mL)</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1.4</td>
<td>11 (34%)</td>
<td>8 (25%)</td>
<td>13 (41%)</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>≥1.4</td>
<td>1 (33%)</td>
<td>0 (0%)</td>
<td>2 (67%)</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Association between pretreatment levels of sPD-L1 L and clinical responses</th>
<th>sPD-L1 L of pretreatment (baseline, ng/mL)</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.5</td>
<td>6 (20%)</td>
<td>21 (54%)</td>
<td>0 (0%)</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>≥0.5</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>5 (100%)</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Fisher exact test $P = 0.025$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D. Ipilimumab or ipilimumab plus sargramostim</th>
<th>sPD-L1 L of pretreatment (baseline, ng/mL)</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.5</td>
<td>30 (22%)</td>
<td>31 (22%)</td>
<td>78 (556%)</td>
<td>139</td>
<td></td>
</tr>
<tr>
<td>≥0.5</td>
<td>2 (17%)</td>
<td>2 (17%)</td>
<td>8 (66%)</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Fisher exact test $P = 0.55$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>F. Anti-PD-1 antibody</th>
<th>sPD-L1 L of pretreatment (baseline, ng/mL)</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.5</td>
<td>14 (43%)</td>
<td>8 (24%)</td>
<td>14 (43%)</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>≥0.5</td>
<td>1 (50%)</td>
<td>0 (0%)</td>
<td>1 (50%)</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>
decreased at 8 months after therapy. Upon closer exploration of the levels of sPD-L1 after the initial analyses, the treatment resulted in a 1.5-fold increase in the calculated shortest variant of sPD-L1 (red line, Supplementary Fig. S12). Despite limits of sample availability, these data support our findings in the ipilimumab–bevacizumab treated cohort.

Figure 4.
Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. A, Patients with pretreatment levels ≥1.4 ng/mL sPD-L1 all and/or ≥0.5 ng/mL sPD-L1 L. B, Patients with ≥1.5-fold increases in sPD-L1 all and/or sPD-L1 L after 5 months of treatment.
The associations between sPD-L1 and clinical responses were further validated in 151 patients treated on the ECOG 1608 trial (randomized phase II of ipilimumab 10 mg/kg plus sargramostim versus ipilimumab 10 mg/kg, NCT01134614; ref. 23). Nine of 10 patients with high pretreatment levels of sPD-L1 experienced progressive disease. Eight of 12 patients with high pretreatment levels of sPD-L1 experienced progressive disease (Fisher exact test $P = 0.04$ and $P = 0.55$, respectively, Table 1C and 1D).

Next, we focused on kinetic changes of sPD-L1 within the ipilimumab-only arm (73 patients). Many patients with $\geq 1.5$-fold increase in sPD-L1 within 4.5 months suffered progressive disease (Supplementary Fig. S13A–S13F). Patients with $\geq 1.5$-fold increases in sPD-L1 after 5 months of treatment were significantly associated with partial responses, compared with patients with $< 1.5$-fold increases (75% vs. 27%, Fisher exact test $P = 0.039$, Fig. 6A; Supplementary Fig. S13G). Patients with $\geq 1.5$-fold increases in sPD-L1 after 5 months of treatment did not show significant associations with partial responses (56% vs. 36%, Fisher exact test $P = 0.42$, Fig. 6B; Supplementary Fig. S13H). These data are consistent with our findings in the ipilimumab–bevacizumab cohort. Patient EP45, who had a subtle increase of sPD-L1 (1.5-fold increase), developed a partial response. Secondary review noted a relative decrease in sPD-L1, which resulted in $\geq 1.5$-fold increase in the calculated shortest variant of sPD-L1 (shown in Fig. 6C).

To further investigate whether the sPD-L1 relationship between clinical responses was restricted to ipilimumab-based treatment, samples were assayed from 35 patients treated with PD-1 blocking antibody. Four patients had high pretreatment concentrations of either sPD-L1 or sPD-L1, and two of these patients experienced progressive disease (Table 1E and F; Supplementary Fig. S14A and S14B). Kinetic changes of sPD-L1 as a function of treatment were also examined. All eight patients with $\geq 1.5$-fold increases in sPD-L1 after 5 months of treatment experienced partial responses, and all four patients with $\geq 1.5$-fold increases in sPD-L1 after 5 months of treatment experienced partial responses (Fisher exact test $P = 0.007$ and $P = 0.103$, respectively; Fig. 6D and E; Supplementary Fig. S14A–S14H). These data are consistent with our findings from the ipilimumab treatment cohorts. However, in contrast to that seen following ipilimumab, there were no increases in circulating cytokines in these patients whether or not they had increases in sPD-L1 (Supplementary Fig. S15).

**Discussion**

Great advances in the treatment of patients with metastatic melanoma have been realized over the last decade, in large part due to the development of immune checkpoint inhibitors. Patients that survive 3 years after ipilimumab therapy are likely to experience continued benefit with up to 10 years of follow-up (27). PD-1 blockade produces higher response rates than ipilimumab (28). Prognostic and predictive biomarkers for which patients will fail therapy early and which patients will develop durable clinical benefit are needed. The development of future treatments will need to account for the dynamic changes in immune responses as a function of treatment.

Elevated sPD-L1 has been associated with worse clinical outcomes in both renal cell carcinoma and multiple myeloma. Studying metastatic melanoma, here we identified multiple splice variants of PD-L1 and report elevated sPD-L1 in sera from metastatic melanoma patients. Patients with the highest pretreatment sPD-L1 concentrations had a tendency towards rapidly progressive disease after ipilimumab-based therapy. Early changes in sPD-L1 concentrations after checkpoint inhibition therapy did not correspond with benefit. However, rise in sPD-L1 after 5 months of treatment correlated with partial responses in cohorts of patients treated with ipilimumab-based therapy. Rise in sPD-L1 after anti–PD-1 treatment was also associated with partial responses. Changes in circulating cytokines, corresponding with changes in sPD-L1 after anti–CTLA-4-based therapy, were not seen in patients receiving PD-1 blockade, suggesting different mechanisms for increasing circulating sPD-L1 are associated with different immune checkpoint inhibitors.

The sources of sPD-L1 in patients with cancer remain unclear. We found that alternative splicing of PD-L1 occurs in all melanoma cell lines. Alternative splicing of membrane proteins can result in new in-frame stop codons before the transmembrane domain and lead to the secretion of splice variants (29–32).
Figure 6.
sPD-L1 in sera of melanoma patients receiving either ipilimumab in ECOG 1608 trial or anti–PD-1 antibody. A and B, Comparison between long-term or delayed increases and nonincrease in sPD-L1 in melanoma patients receiving ipilimumab. C, Different characters in secretion of sPD-L1 in patient EP45 after ipilimumab treatment. D and E, Comparison between long-term or delayed increases and nonincrease in sPD-L1 in melanoma patients receiving anti–PD-1 antibody. Red line indicates a greater than 1.5-fold increases in sPD-L1 after 5 months of treatment, and black line indicates <1.5-fold increases in sPD-L1 after 5 months of treatment (shown in A, B, D, and E). Pink lines represent changes of sPD-L1<sup>a</sup> and sPD-L1<sup>L</sup>, and a red line stands for a >1.5-fold increases in the shortest sPD-L1 variant (shown in C). Fisher exact tests were performed based on window from 5 to 11 months posttreatment (Supplementary Figs. S13G and S13H and S14G and S14H). P < 0.05 are considered statistically significant.
Indeed, three splice variants lack the transmembrane domain and result in the secretion of sPD-L1. In one variant, loss of the intracellular domain due to splicing also led to secretion, suggesting that the intracellular domain may stabilize PD-L1 on the cell surface.

Aberrant alternative splicing activities occur in a variety of cancers, and these events affect the expression of transcription factors, cell signaling factors, and membrane proteins (29). Functional changes of these spliced proteins are involved in the development, proliferation, and metastasis of cancers (29, 33, 34). We show here that such splicing activities for PD-L1 affect metastatic melanoma. High pretreatment concentrations of sPD-L1 that were associated with worse outcomes to checkpoint blockade may reflect the extent of increased splicing activities in melanoma cells as well as tumor burden. This idea is supported by the increased splice variants of sPD-L1 observed in BRAF inhibitor resistant melanoma cell lines. Selective pressures from BRAF inhibitors are also associated with induced splicing variants of BRAF V600E (26).

The balance between a protumor inflammation and antitumor immune response is complex. Inflammation is a hallmark of cancer (35) and can cause tumor progression (36, 37). Cytokines also can produce an antitumor immune response and are essential for antitumor immune effector function (36, 38). As part of the regulatory homeostatic response, cytokines such as IFNγ and TNFα induce expression of PD-L1 in a variety of cancer cells (39–42). CD8+ T cells at tumor sites correlate with PD-L1 expression and clinical responses (43, 44). Our data demonstrated that cytokines, such as IFNγ, IFNα, and TNFα, increase splicing activities of PD-L1 leading to secretion of sPD-L1 directly by tumor cells. PD-L1 cell surface expression was parallel to sPD-L1 secretion in response to cytokines in melanoma cancer cells, and patients with moderate pretreatment levels of sPD-L1 experienced favorable clinical outcomes. In addition, most patients with favorable clinical responses showed detectable levels of cytokines in their pretreatment sera. Moderate pretreatment levels of sPD-L1 may indicate existing antitumor immune responses in some patients. Pretreatment sPD-L1 concentrations may be related to preexisting protumor inflammatory responses.

Circulating sPD-L1 in the sera of patients may have multiple sources produced by distinct mechanisms. These include intrinsic splicing activities in tumor cells, protumor inflammatory responses, and antitumor immune responses. Patients with high pretreatment sPD-L1 had poor outcomes, perhaps due to large tumor burden, increased aberrant splicing activities in tumor cells, or an exhausted antitumor immune response, which may be difficult to overcome with single checkpoint blockade. As a result, qualitative differences in pretreatment sPD-L1 concentrations could represent either favorable or unfavorable factors for clinical outcomes depending on the source of sPD-L1. Favorable clinical outcomes with immune checkpoint blockade occurred predominately in patients with moderate to low pretreatment sPD-L1. Moderate sPD-L1 may reflect pre-existing antitumor immune responses. Although clinical responses in patients with moderate pretreatment sPD-L1 concentrations were most impressive in the ipilimumab plus bevacizumab trial, this was not seen in the ipilimumab arm of the ECOG 1608 trial. However, cross trial comparisons in the cohorts may not be appropriate, given that it would be comparing different combinations and different treatment doses in nonrandomized cohorts. Multiplex analysis of pretreatment sPD-L1 and cytokine concentrations in patients may help to distinguish PD-L1 splicing activities from tumor cells versus inflammatory responses.

We show that circulating sPD-L1 levels frequently increase as the result of treatment with checkpoint blockade. Patients with long-term or delayed increase in sPD-L1 correspond with clinically beneficial outcomes. This scenario occurred in around 70% of total patients with partial responses. Furthermore, sPD-L1 concentrations are associated with concentrations of circulating cytokines after ipilimumab-based therapy. As secretion of sPD-L1 can result from cytokine induction, cell stress, cell injury, and cell death, increases in sPD-L1 by checkpoint blockade may indirectly reflect antitumor immune responses. Long-term or delayed increases in sPD-L1 following treatment suggest that the antitumor immune responses can overcome the negative barriers of PD-L1 and other potential immune suppressive factors in the tumor microenvironment. Short-term increases in sPD-L1 from treatment were associated with progressive disease and shorter survival in subsets of patients. This suggests a challenge in the early evaluation of sPD-L1 rise and discerning whether rising sPD-L1 is because of tumor progression or activated antitumor immune responses, and determining whether antitumor immune responses could overcome immune suppressive barriers in long term. On the basis of our initial analyses of four cohorts of patients, the minimum time needed to distinguish whether an increase in sPD-L1 increases the likelihood of clinical benefit is approximately 5 months. Further detailed collection of long-term samples from both responding and nonresponding patients is needed to investigate association of sPD-L1 changes and clinical outcomes. Preliminary studies on this were investigated (Supplementary Fig, S16 and S17). Increases in sPD-L1 concentration occurred with both CTLA-4 and PD-1 blockade, indicating that sPD-L1 concentration may be an indicator of beneficial clinical outcomes. Patients receiving CTLA-4 blockade showed associations between increases of sPD-L1 and cytokine production, whereas this association was not observed in patients receiving PD-1 blockade alone. This may be related to the mechanism of action for these drugs, with anti–CTLA-4 acting globally on immune function and anti–PD-1 affecting primarily the tumor microenvironment.

Although tumors that express PD-L1 may produce secreted splice variants detectable in the circulation, the tumor may not be the only source of sPD-L1. Our and others’ (20) data (Supplementary Fig. S18) also indicated that sPD-L1 can be secreted from human myeloid DC in the presence of cytokines and LPS during DC maturation. sPD-L1 from myeloid DC in patients without treatment can’t be ruled out. However, secretion of sPD-L1 results from cytokine presence, cell stress, cell injury and cell death, and long-term or delayed increases in sPD-L1 were associated with favorable clinical outcomes during treatment with checkpoint inhibitors, and the peak posttreatment sPD-L1 corresponded with clinical tumor regression. In contrast, human myeloid DC expressed high levels of PD-L1 and suppressed T-cell activation, and T cells conditioned with PD-L1 blocked myeloid DC inhibited human ovarian carcinoma growth (45). We suggest that sPD-L1 mainly originated from the tumor in patients who had favorable clinical responses after checkpoint blockade.

sPD-L1 secretion in melanoma is associated with three major splice variants that may be differentially secreted. In addition, secretion of sPD-L1 may more precisely reflect cytokine stimulation, because there are dissociations between constitutive expression of membrane-bound PD-L1 and increases in sPD-L1. PD-L1
variants should be taken into consideration in assay development as there may be difference in biological significance across variants, although sPD-L1 is more significantly associated with clinical outcomes. We found no associations of sPD-L1 with age, gender, M-stage, and LDH in the current evaluated patient cohorts (Supplementary Table S2). These data suggest that high sPD-L1 and LDH concentrations may not be related in terms of prognostic or predictive values. It remains unclear whether sPD-L1 is a clinically significant systemic immunosuppressant.

Immune therapy is not as effective in patients with symptomatic, rapidly progressive disease. Although the number of patients with high sPD-L1 prior to anti–PD-1 therapy is small, we found it interesting that some of these benefited from PD-1 blockade. In patients for whom we had plasma samples after 5 months on therapy, we found that those who had 1.5-fold increases in sPD-L1 plasma concentrations were more likely to achieve partial responses not only to ipilimumab or ipilimumab–bevacizumab treatment, but also anti–PD-1 therapy. Prospective validation of the prognostic and kinetics of sPD-L1 alone or in the context of a multiple assay incorporating cytokines, such as IFNs and TNF-α, may help establish whether kinetic changes in sPD-L1 after immune checkpoint are effective in predicting not only RECIST criteria responses, but also durable clinical benefit.

In summary, sPD-L1 exists as several variants that can originate from both tumor and immune cells. sPD-L1 may serve as a meaningful and practical dynamic biomarker for the prediction of durable efficacy to immunotherapy agents alone or in the context of additional factors. Soluble circulating factors offer a practical means for monitoring patient outcomes while improving our mechanistic understanding.

Disclosure of Potential Conflicts of Interest
J. Zhou has ownership interest in a pending patent application for soluble PD-L1 as a biomarker. X. Wu has ownership interest in compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-L1 isoforms, per institution policy (patent application is pending). G. Dranoff is Global Head, Exploratory Immuno-oncology at Novartis, reports receiving a commercial research grant from Novartis and Bristol-Myers Squibb, has ownership interest (including patents) in Novartis, and is a consultant/advisory board member for Novartis. F. Freeman has ownership interest (including patents) in Roche, Merck, Bristol-Myers Squibb, Novartis, EMD Serono, AstraZeneca, Roche, Bristol-Myers Squibb, Novartis, Eli Lilly, Bristol Myers Squibb, Seattle Genetics, Bethyl Laboratories, and Surface Oncology, and has an immediate family member with ownership interest in Roche and Novartis and who is a consultant/advisory board member of Surface Oncology and Novartis. F.S. Hodi reports receiving a commercial research grant from Bristol-Myers Squibb to institution, has ownership interest (including patents) in royalty to institution per institutional policy on patent pending. MCA related disorders, institutional patent pending soluble PD-L1 as a biomarker for immune therapy; no financial interest to date, is a consultant/advisory board member for Merck, EMD Serono, Genentech, Novartis, and Amgen. No potential conflicts of interest were disclosed by the other authors.

Disclaimer
The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

Authors' Contributions
Conception and design: J. Zhou, G. Dranoff, F.S. Hodi
Development of methodology: J. Zhou, X. Liao, M. Piesche, G.J. Freeman, F.S. Hodi
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J. Zhou, X. Liao, J. Li, X. Wu, L.H. Butterfield, M.P. Manos, L.M. Eastman, F.S. Hodi
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J. Zhou, K.M. Mahoney, A. Giobbie-Hurder, F. Zhao, S. Lee, S. Rodig, L.H. Butterfield, G.J. Freeman, F.S. Hodi
Writing, review, and/or revision of the manuscript: J. Zhou, K.M. Mahoney, A. Giobbie-Hurder, F. Zhao, X. Liao, J. Li, X. Wu, M. Piesche, G. Dranoff, G.J. Freeman, F.S. Hodi
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J. Zhou, M. Piesche, M.P. Manos, L.M. Eastman, F.S. Hodi
Study supervision: J. Zhou, F.S. Hodi

Grant Support
A portion of this study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L. Comis, MD and Mitchell D. Schnall, MD, PhD, group co-chair) and supported in part by Public Health Service Grants CA180794, CA118020, CA21115, CA66636, CA23118, CA180867, CA39229, CA188044, and P50CA101942 (G.J. Freeman) from the National Cancer Institute, NIH, and the Department of Health and Human Services. K.M. Mahoney was supported by Claudia Adams Barr Program in Innovative Cancer Research, the 2014 ASCR Basic Cancer Research Fellowship, grant number 14-09-01-MAHO, and the ASCO Young Investigator Award supported by Kidney Cancer Association. F.S. Hodi was supported by NIH CA143832, the Melanoma Research Alliance, the Sharon Crowley Martin Memorial Fund for Melanoma Research and the Malcolm and Emily MacNaught Fund for Melanoma Research at Dana-Farber Cancer Institute, Genentech/Roche, and Bristol-Myers Squibb.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 16, 2016; revised March 13, 2017; accepted May 2, 2017; published OnlineFirst May 18, 2017.

References

www.aacrjournals.org Cancer Immunol Res; 5(6) June 2017 491

Published OnlineFirst May 18, 2017; DOI: 10.1158/2326-6066.CIR-16-0329

Downloaded from cancerimmunolres.aacrjournals.org on December 21, 2021. © 2017 American Association for Cancer Research.
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade


Updated version

Access the most recent version of this article at:
doi:10.1158/2326-6066.CIR-16-0329

Supplementary Material

Access the most recent supplemental material at:
http://cancerimmunolres.aacrjournals.org/content/suppl/2017/05/18/2326-6066.CIR-16-0329.DC1

Cited articles

This article cites 45 articles, 13 of which you can access for free at:
http://cancerimmunolres.aacrjournals.org/content/5/6/480.full#ref-list-1

Citing articles

This article has been cited by 26 HighWire-hosted articles. Access the articles at:
http://cancerimmunolres.aacrjournals.org/content/5/6/480.full#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link
http://cancerimmunolres.aacrjournals.org/content/5/6/480.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.